Innovent Biologics (suzhou) Co. Ltd.

This study tests a drug called IBI363 given before surgery to people with stage II or III non-small cell lung cancer that can be removed. The goal is to see if the drug can shrink or eliminate the tumor before the operation. About 10 participants will receive IBI363 and then have…

This study tests a new drug called IBI3003 in 255 adults with multiple myeloma that has returned or not responded to prior treatments. Participants will receive either IBI3003 or one of two standard treatment combinations chosen by their doctor. The main goal is to see if IBI3003…

This study tests a new drug combination (IBI3005) in 282 adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to check safety and see if the treatment can shrink tumors. It is an early-phase trial, so it focuses on finding the rig…

This study tests a new drug called teprotumumab N01 against standard steroid treatment for active thyroid eye disease, a condition that causes eye bulging and discomfort. About 92 adults with moderate-to-severe symptoms will receive either the new drug or steroids to see which be…

This early-stage study tests a new drug called IBI3031 in 66 people with moderate-to-severe thyroid eye disease. The main goal is to check if the drug is safe and how the body processes it. Participants will receive either the drug or a placebo by injection, and researchers will …

This study observes 50 adults with advanced ROS1-positive non-small cell lung cancer whose disease worsened after treatment with entrectinib. Researchers will track how well taletrectinib works in real-world settings, including tumor shrinkage and safety. The goal is to understan…

This early-stage study tests a single injection of a new drug, IBI3016, in 30 Chinese adults with mild to moderate hypertension who are not currently on blood pressure medication. The main goal is to check safety and how the drug moves through the body, with a secondary look at i…

This early-stage study tests a new medicine called IBI3033 in 16 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants will receive either IBI3033 or a placebo over 12 weeks, with follo…

This early-stage study tests whether a new insulin formula (IBI3035) works similarly to an approved insulin (Awiqli) in healthy men. Researchers will measure how the drug moves through the body and how it affects blood sugar after a single injection. The goal is to gather safety …